Around for over 150 years, barbiturate abuse has plagued the United States since its invention. Originally used to treat seizure disorders, insomnia, tension headaches, and anxiety, the sedative effects of barbiturates made them popular on the illicit drug market.
Sometimes called sedatives, hypnotics, and tranquilizers, barbiturates have largely fallen out of use except for specific circumstances, including conditions that have not responded to other treatments, surgery, physician-assisted suicide, and government-sanctioned executions.
Despite their limited medical use, barbituates continue to be popular in the United States on the street and as a mixing agent with other drugs.
What Are Barbiturates?
Barbiturates are a sedative-hypnotic central nervous system depressant, a schedule II drug in the United States.
Medically, barbiturates help treat seizure disorders that have not responded to other medications, withdrawal symptoms in infants, preoperative anxiety, and induce unconsciousness for surgical procedures. The drug is administered intravenously or in oral tablet form.
When barbiturates bind to neurotransmitters in the brain, they suppress and slow down nerve impulses throughout the body, which creates the sedative effect.
Barbiturates have a high risk of producing psychological and physical dependence and dangerous withdrawal symptoms. And because of the dangers associated with this drug, it is increasingly replaced by safer alternatives.
How Barbiturates Affect the Central Nervous System
Barbiturates exert their primary effects by enhancing gamma-aminobutyric acid (GABA) activity at GABA-A receptors, specifically binding to alpha- and beta subunits at distinct transmembrane pockets separate from benzodiazepine binding sites. At low doses, they function as positive allosteric modulators, prolonging chloride ion channel opening. At higher doses, they act as direct agonists at GABA receptors, causing profound CNS depression.
You’ll experience increased chloride influx, which hyperpolarizes neurons and raises the firing threshold. Barbiturates also block AMPA and kainate glutamate receptors, reducing excitatory transmission. They inhibit voltage-dependent calcium channels, decreasing neurotransmitter release. Beyond GABA receptors, barbiturates bind to other ligand-gated ion channels, contributing to their broad spectrum of CNS effects. Additionally, barbiturates inhibit voltage-gated sodium channels, which contributes to their anticonvulsant and anesthetic properties.
When you combine barbiturates with alcohol or benzodiazepines, you’ll amplify sedation, respiratory depression, and overdose risk. Clinical dosing requires careful monitoring due to these potent drug interactions. Chronic use leads to physical dependence, with tolerance and withdrawal symptoms developing over time with consistent use.
Types of Barbiturates, Generic and Brand Names
There are over 50 different types of barbiturates sold under various generic and brand names.
They fall into four categories based on how quickly they affect the body. The faster they set in, the stronger they are considered.
The four types of barbiturates, their uses, and examples are below from strongest to weakest.
Barbiturates fall into four categories based on how long they work in your body. Ultra-short-acting types like thiopental induce anesthesia within one minute, while short-acting formulations such as pentobarbital provide sedation for up to six hours. Intermediate-acting barbiturates like amobarbital require doses of 30-50 mg taken multiple times daily. Long-acting phenobarbital controls seizures with once-daily dosing. Each classification carries distinct drug interaction risks with alcohol, opioids, and sedatives that you’ll want to understand thoroughly.
Ultra Short-Acting Barbiturates
Ultra short-acting barbiturates are injected intravenously for anesthesia purposes; the effects set in about a minute later and last one to three hours.
Examples of ultra short-acting barbiturates include:
- Methohexital (Brevital)
- Thiamylal (Surital)
- Thiopental sodium (Pentothal)
When you’re inducing anesthesia, thiopentone and methohexitone deliver effects within one minute of intravenous administration, making them ideal for rapid-sequence intubation and brief procedures. You’ll find their duration limited to approximately 30 minutes, which suits short interventions like cardioversion and fracture reduction but restricts thiopentone’s use as a sole agent to procedures under 15 minutes. Be aware that concurrent administration with narcotics, antihistamines, or other sedatives intensifies CNS depression, requiring careful dosage adjustments to prevent respiratory compromise.
Thiopentone and Methohexitone
Ultra short-acting barbiturates represent a specialized class of anesthesia agents, with thiopental sodium and methohexital sodium serving as the primary examples. Among the types of barbiturates, these CNS depressants deliver rapid induction with effects lasting approximately 30 minutes.
You’ll find methohexital is 2-5 times more potent than thiopental on a milligram basis. For induction, you’d administer thiopental at 2.5-4.5 mg/kg IV, while methohexital requires lower doses due to its increased potency.
Prescription safety demands attention to critical drug interactions. Both agents interact dangerously with alcohol, opioids, and sedatives. You must avoid thiopental in patients with porphyria or liver disease. Methohexital causes paradoxical excitement and requires careful monitoring in patients with sleep apnea. Extravasation of thiopental risks severe tissue necrosis, requiring precise IV placement.
Rapid Onset and Offset
Building on thiopental and methohexital, the broader category of ultra-short-acting barbiturates includes thiamylal sodium, which shares their rapid pharmacokinetic profile. You’ll find these Schedule III drugs produce anesthesia within one minute of intravenous administration, with effects lasting approximately 30 minutes due to rapid redistribution from the brain.
When you’re administering thiamylal sodium, you’ll use doses ranging from 2.5 to 10 mg/kg, delivered as bolus or infusion. Their high lipid solubility drives the quick CNS depression and equally swift recovery, giving you precise anesthetic control.
You must monitor for interactions with narcotics, sedatives, and anticoagulants, as these compounds cause broad CNS depression. Avoid use in patients with porphyria, liver disease, or pregnancy. Don’t administer to nursing mothers since excretion occurs in breast milk.
Short-Acting Barbiturates
Short-acting barbiturates are injected or taken orally to treat sleep disorders or before surgeries; these take effect several minutes after administration and last three to five hours.
Examples of short-acting barbiturates include:
- Secobarbital (Seconal)
- Pentobarbital (Nembutal)
Short-acting barbiturates like pentobarbital and secobarbital work for approximately two hours. You’ll find these agents enhance GABA-A receptor activity, increasing chloride ion flux and depressing your central nervous system.
Short-acting barbiturates pose the highest acute overdose danger due to rapid onset and peak intensity. Fatal outcomes multiply when you combine barbiturates with alcohol or other sedatives. Respiratory depression leads directly to coma and death, making dosage precision non-negotiable.
Intermediate-Acting Barbiturates
Intermediate-acting barbiturates are taken orally pre-surgery or for sleep disorders and anxiety; the effects set in roughly an hour later and last for six to eight hours.
Examples of intermediate-acting barbiturates include:
- Amobarbital (Amytal)
- Butabarbital (Butisol)
- Butalan
- Burabarb
- Sarisol
- Alurate
- Somnifaine
- Oramon
- Allonal
Intermediate-acting agents such as amobarbital and butalbital can be effective for three to six hours, with amobarbital’s sedative dose ranging from 30-50 mg taken two to three times daily. Intermediate-acting options require careful monitoring for respiratory system depression, particularly when combined with other CNS depressants.
Your addiction risk escalates quickly, physical dependence develops with daily use beyond one month. Tolerance builds rapidly, forcing dose increases to achieve the same effects. Short- and intermediate-acting formulations can accelerate dependence onset through abrupt clearance patterns.
Long-Acting Barbiturates
Long-acting barbiturates are taken orally to treat alcohol withdrawal, seizure disorders, anxiety, and insomnia; the effects take about an hour and can last up to twelve hours.
Examples of long-acting barbiturates include:
- Phenobarbital (Luminal)
- Primidone (Mysoline)
- Mephobarbital (Mebaral)
- Methylphenobarbital (Phemiton)
- Prominal
Long-acting barbiturate classifications include phenobarbital, which has a half-life of roughly 92 hours. This extended duration creates bioaccumulation risks with repeated dosing. You should note that phenobarbital’s absorption peaks within two to four hours, achieving 90% bioavailability in adults.
When you’re managing seizures that require sustained control, phenobarbital stands as the dominant long-acting barbiturate with effects lasting well beyond six hours. You’ll find its extended duration, ranging from 10 to 16 hours, makes it particularly effective for maintaining consistent anticonvulsant coverage throughout the day. This pharmacokinetic profile allows you to dose patients as infrequently as once daily at bedtime, starting at 100-125 mg for barbiturate-naive individuals.
Phenobarbital Dominates Treatment
Although benzodiazepines remain first-line for acute seizure management, phenobarbital dominates long-term seizure control as the oldest anticonvulsant still in common clinical use. Discovered in 1912, this barbiturate replaced bromide therapy and offered patients seizure-free outcomes with fewer adverse effects. Among sedative drugs, phenobarbital’s 80-120 hour half-life provides sustained therapeutic coverage.
Key Clinical Applications:
- Neonatal seizures: First-line treatment due to aggressive intervention requirements
- Status epilepticus: Third-line option when benzodiazepines and phenytoin fail
- Partial onset seizures: Demonstrates clinical advantage over carbamazepine
You’ll administer phenobarbital orally, intramuscularly, or via slow intravenous infusion. The WHO recommends it as first-line therapy in developing countries. It treats all seizure types except absence seizures, making it versatile for wide-ranging epilepsy management protocols.
Duration Exceeds Six Hours
Because their duration exceeds six hours, long-acting barbiturates like phenobarbital and primidone provide sustained anticonvulsant coverage that shorter-acting agents can’t match. You’ll find these medications work by enhancing GABAA receptor activity, elevating your seizure threshold while limiting focal spread.
When you’re targeting therapeutic plasma concentrations of 10-40 mcg/mL, you can often achieve control with once-daily dosing due to phenobarbital’s prolonged half-life. Primidone dosing starts at 100-125 mg at bedtime, titrating up to 2000 mg daily based on response.
You must monitor for drug interactions that increase overdose risk, particularly with other CNS depressants. Never discontinue these medications abruptly, you’ll need slow dose reduction to prevent withdrawal seizures. These agents effectively control tonic-clonic and focal seizures but won’t address absence seizures.
One of the main reasons health care professionals moved away from barbiturates is their high risk of addiction and overdose potential. Barbiturates have an increased risk of users developing a substance use disorder and can cause withdrawal symptoms if you abruptly quit taking them.
You should follow medical advice to avoid dangerous side effects when taking prescription drugs. Even a slight dose increase can cause adverse effects or an accidental overdose.
Talk to a doctor if you plan to stop taking barbiturates, especially if you take high doses; they may recommend medical detox and inpatient treatment.
Which Barbiturates Doctors Prescribe Most Often
Despite the decline in barbiturate prescriptions over recent decades, several compounds remain clinically relevant for specific indications.
Barbiturates may be less common today, but these powerful medications still serve critical roles in modern medicine.
Commonly Prescribed Barbiturates
- Phenobarbital, You’ll encounter this FDA-approved medication most frequently for seizure prevention in pediatric patients. Doctors prescribe it for epilepsy maintenance, status epilepticus, and occasionally anxiety disorders.
- Pentobarbital, Your physician may administer this as a pre-anesthetic agent or for managing heightened intracranial pressure off-label. It’s also used in neonatal withdrawal protocols.
- Secobarbital, You might receive this intermediate-acting barbiturate for presurgical sedation, though prescriptions have decreased substantially.
When you’re taking these medications, watch for interactions with CNS depressants, anticoagulants, and corticosteroids. Barbiturates induce hepatic enzymes, potentially reducing the effectiveness of concurrent medications. Always verify dosing parameters with your prescriber.
Why Barbiturate Classification Guides Clinical Decisions
Given that barbiturate classification directly determines onset speed, duration of effect, and elimination pathways, clinicians rely on these categories to match specific agents to clinical scenarios with precision.
You’ll find that ultra-short-acting agents like thiopental exhibit first-order kinetics at low doses but shift to non-linear elimination during prolonged infusions. This pharmacokinetic variability demands careful dose adjustments and continuous monitoring.
Key classification-driven clinical decisions:
- You’ll select IV phenobarbital for status epilepticus due to rapid onset, while reserving oral formulations for chronic epilepsy maintenance.
- You’ll choose methohexital or thiopental for anesthesia induction when immediate CNS depression is required.
- You’ll implement continuous arterial blood pressure monitoring during high-dose barbiturate coma to maintain adequate cerebral perfusion.
DEA scheduling (II-IV) further dictates your prescribing protocols based on abuse potential.
Barbiturate Street Names
Many street names for barbiturates used today have been around since the 1920s. Most nicknames refer to the original colors or packaging of the pills and capsules. Other slang terms come from the side effects that make them popular among users.
General barbiturate street names include:
- Barbs
- Phennies
- Christmas trees
- Blockbusters
- Downers
- Sleepers
- Tootsies
- Rainbows
The most popular barbiturates found on the illicit market have specific street names. The most common barbiturates and their street names include:
- Phenobarbital (Luminal)– goofballs, purple hearts
- Secobarbital (Seconal)– pinks, reds, red devils, pink ladies, lilys
- Amobarbital (Amytal)– blue velvet, blue heaven, blue devils
- Pentobarbital (Nembutal)– yellow jackets, nembies, Mexican yellows
The time it takes to feel the effects and how long they last vary between pills, but they all share powerful sedative effects and a high risk of overdose.
Barbiturates Side Effects
Barbiturates are central nervous system depressants that bind to neurotransmitters in the brain to cause a sedative effect.
Common barbiturates side effects include:
- Drowsiness
- Delayed physical reactions
- Confusion
- Slurring
- Headache
- Lack of inhibitions
- Vomiting
- Blurry vision
- Low blood pressure
- Increased heart rate
- Slowed breathing
- Impaired judgment
It takes less than a month to develop a tolerance and dependence on barbiturates. Repeated high doses have lasting health effects and dangerous withdrawal symptoms.
Long-term side effects of barbiturates include:
- Memory loss
- Chronic fatigue
- Loss of coordination and balance
- Decreased motor skills
- Mood swings
- Reduced heart rate
- Depression
- Anxiety
- Sleepwalking
- Migraines
- Hallucinations
- Sexual dysfunction
- Congenital disabilities
- Withdrawal
When you’re evaluating barbiturate risks, understanding that all types share a dangerously narrow therapeutic index becomes essential, the gap between an effective dose and a lethal dose remains slim across the entire drug class.
Because of how potent barbiturates are, taking higher than the recommended dose, or mixing them with other substances, including prescription drugs or alcohol, can easily lead to an overdose.
Barbiturate Overdose
The risk of a barbiturate overdose is very high due to its fast-acting nature and potent properties.
In 1945, hospitals in New York reported that one drug overdose death every 36 hours resulted from barbiturate abuse. Barbiturate overdoses are not new or uncommon, but they remain challenging to treat.
Signs of a barbiturate overdose include:
- Diminished consciousness
- Difficulty thinking and expressing themselves
- Slow, slurred speech
- Shallow breathing
- Gasping for air
- Weak pulse
- Damp or clammy skin
- Extreme confusion or disorientation
- Unresponsive to stimuli
- Coma
Treatment for Barbiturates Addiction
If you or a loved one is struggling with an addiction to sedatives, help is available. At Northridge Addiction Treatment Center, your lasting recovery and well-being are our top priority.
We ensure your health and comfort during painful withdrawal symptoms with medical detox and 24-hour medical care in our private, serene residential treatment facility.
Our licensed and compassionate team utilizes evidence-based treatment and therapies with a personalized, comprehensive approach, guaranteeing a solid foundation for recovery when you finish treatment.
Northridge Addiction Treatment Center helps you rediscover your life by creating a path for you to take the first steps in your recovery journey.
Our caring treatment specialists are eager to help you. Reach out now.
Frequently Asked Questions
Which Countries Produce the Most Barbiturates Globally?
You’ll find India and China leading global barbiturate production. India dominates active pharmaceutical ingredient manufacturing through companies like Sun Pharmaceutical and Aurobindo Pharma, while China excels in large-scale production capabilities. Both countries drive low-cost generic manufacturing that’s FDA-approved for Western markets. North America currently holds 41.70% market share, but Asia-Pacific’s 7.75% CAGR growth rate means you’re seeing a significant shift toward Indian and Chinese production dominance.
What Are Common Street Names Used for Different Barbiturates?
You’ll encounter various street names for barbiturates based on their appearance. Phenobarbital goes by “purple hearts” or “goofballs.” You’ll hear secobarbital called “reds,” “red devils,” or “downers.” Amobarbital’s known as “blue heavens” or “blue devils.” Pentobarbital’s referred to as “yellow jackets” or “nembies.” Recognizing these terms is clinically important when evaluating patient drug histories, identifying potential interactions with CNS depressants, and assessing overdose risks requiring dosage-specific interventions.
Can Barbiturates Interfere With Birth Control Effectiveness?
Yes, barbiturates can drastically reduce your birth control’s effectiveness. They induce hepatic CYP3A enzymes, which accelerate metabolism of estrogen and progestin by 40-60%. This interaction affects combined hormonal contraceptives (pills, patch, ring), progestin-only pills, and implants. You’ll want to use backup methods like condoms or switch to unaffected options, Depo-Provera injections or IUDs aren’t impacted. Watch for breakthrough bleeding, which signals potential contraceptive failure.
How Is Barbituric Acid Chemically Modified to Create Different Barbiturate Compounds?
You’ll find that barbituric acid becomes pharmacologically active through strategic modifications at two key positions. At C-5, you’re adding geminal dialkyl groups (like in amobarbital or pentobarbital) to increase lipophilicity, enabling blood-brain barrier penetration. At C-2, you can substitute sulfur for oxygen, creating thiobarbiturates with faster onset. These modifications transform the inactive parent compound into clinically useful sedatives, anesthetics, and anxiolytics with varying potencies and durations.
Are Barbiturates Used in Euthanasia or End-Of-Life Care?
Yes, you’ll find barbiturates historically served as the primary agents in medical aid-in-dying protocols. Physicians prescribed pentobarbital and secobarbital at lethal doses, typically 90-100 pills crushed into solution. However, you’re now seeing these drugs largely replaced due to availability issues and cost increases. Current protocols combine diazepam, morphine, and phenobarbital (DDMAPh), though you should note these combinations produce longer median times to death than traditional barbiturate-only regimens.
